Henry et al. showed that aspirin inhibited the growth of PI3K-mutant breast cancer by activating AMP-activated protein kinase (AMPK) and inhibiting the mammalian target of rapamycin complex 1 (mTORC1), independent of its effects on cyclooxygenase-2 (COX-2) and nuclear factor-kappa B (NF-κB)34. The gene discussed is PTGS2; the disease is breast carcinoma.